Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US12049628B2 · kind B2 · utility
0Cited by
21References
44Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 26, 2022 |
| Grant date | Jul 30, 2024 |
| Priority date | — |
| Expiry date | Mar 6, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.